Keyword: Foundation Medicine
Roche inked a 15-year partnership with Illumina in oncology, which will include collaborating on new companion diagnostic tests and indications.
The field has seen setbacks, but a steady march of clinical data and engineering successes have shown that these ideas can work when done right.
A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.
Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.
With new data exploring lung cancer biomarkers, Roche says that DNA blood tests could soon replace tissue biopsies for picking targeted treatments.
Foundation Medicine brought on Priti Hegde to be chief scientific officer and oversee its clinical product development and cancer genomics work.
Thrive debuted with $110 million, liquid biopsy technology from Johns Hopkins and Third Rock's Steve Kafka at the helm to catch cancer earlier.
Bayer teamed up with Foundation Medicine for diagnostic tests for several of its cancer therapies—starting with the tissue-agnostic Vitrakvi.
Roche’s VP of global oncology strategy, Cindy Perettie, will become the next CEO of Foundation Medicine, which it acquired last year for $2.4 billion.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.